Scribd Logo
Upload

Welcome to Scribd!

  • 31 views

    CSTUDY Jan22 PGDIT AI8 Main 20211123132726

    Uploaded by

    Cooking with Khanyi
    BioIntelliSense, a remote patient monitoring startup, raised $45 million in a Series B funding round led by Chimera to grow its business globally. The company created two FDA-cleared wearable devices, the BioSticker and BioButton, that can continuously monitor patients' vital signs outside hospitals for up to 30 and 60 days respectively. The funding will help BioIntelliSense expand its footprint and operationalize virtual care programs for healthcare providers and payers seeking to deploy effortless medical-grade monitoring and advanced analytics.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    CSTUDY Jan22 PGDIT AI8 Main 20211123132726

    Uploaded by

    Cooking with Khanyi
    31 views3 pages
    BioIntelliSense, a remote patient monitoring startup, raised $45 million in a Series B funding round led by Chimera to grow its business globally. The company created two FDA-cleared wearable devices, the BioSticker and BioButton, that can continuously monitor patients' vital signs outside hospitals for up to 30 and 60 days respectively. The funding will help BioIntelliSense expand its footprint and operationalize virtual care programs for healthcare providers and payers seeking to deploy effortless medical-grade monitoring and advanced analytics.

    Original Description:

    THESE ARE DOCUEMNTS IN ORDER FOR ME TO DOWNLOAD

    Original Title

    CSTUDY_Jan22_PGDIT_AI8_Main_20211123132726

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    BioIntelliSense, a remote patient monitoring startup, raised $45 million in a Series B funding round led by Chimera to grow its business globally. The company created two FDA-cleared wearable devices, the BioSticker and BioButton, that can continuously monitor patients' vital signs outside hospitals for up to 30 and 60 days respectively. The funding will help BioIntelliSense expand its footprint and operationalize virtual care programs for healthcare providers and payers seeking to deploy effortless medical-grade monitoring and advanced analytics.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    31 views3 pages

    CSTUDY Jan22 PGDIT AI8 Main 20211123132726

    Uploaded by

    Cooking with Khanyi
    BioIntelliSense, a remote patient monitoring startup, raised $45 million in a Series B funding round led by Chimera to grow its business globally. The company created two FDA-cleared wearable devices, the BioSticker and BioButton, that can continuously monitor patients' vital signs outside hospitals for up to 30 and 60 days respectively. The funding will help BioIntelliSense expand its footprint and operationalize virtual care programs for healthcare providers and payers seeking to deploy effortless medical-grade monitoring and advanced analytics.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 3

    Case Study

    PROGRAMME Postgraduate Diploma in Information Technology Management


    MODULE Artificial Intelligence
    YEAR ONE (1)
    INTAKE January 2022
    TOTAL MARKS 100
    FORMATIVE ASSESSMENT 1 [100 Marks]

    Remote monitoring startup BioIntelliSense raises $45 million in Series B funding

    Remote patient monitoring company BioIntelliSense scored $45 million in a Series B funding round. To date, the
    Colorado-based startup has raked in roughly $82 million. Chimera (UAE) led the round with participation from 7wire
    Technology Partners, Mary Tolan of Chicago Pacific Founders, James Murren, formerly of MGM Resorts
    International, as well as Pendrell Corporation, Royal Philips and Fresenius Medical Care North America.
    WHAT THEY DO
    The company has created two wearable products that let clinicians collect patient data outside the hospital. The first is
    called the BioSticker, which is a wearable body sticker that is able to capture medical data and insights and transmit that
    data wirelessly to healthcare providers. It also includes analytics for early detection capabilities. The FDA-cleared product is
    able to continuously monitor for 30 days.
    The second tool is called the BioButton, which can be used for continuous vital sign monitoring for 60 days. The tool is able
    to capture temperature, respiratory rate and heart rate at rest.
    WHAT IT’S FOR
    The company says that the new cash will help it grow and expand globally.
    "The Remote Patient Monitoring market is in hyper-growth mode with projections reaching USD $117.1 billion by 2025,"
    noted Lee Shapiro, former CFO of Livongo Health and Co-founder and Managing Partner at 7wireVentures. "BioIntelliSense
    is poised to grow its footprint with provider and payer organizations seeking to accelerate and operationalize their virtual
    care programs by deploying effortless medical-grade monitoring and advanced analytics that are built for scale."
    MARKET SNAPSHOT
    Remote patient monitoring has been a hot topic in digital health for some time, however, during the COVID-19 pandemic,
    the technology caught the eye of clinicians and investors.
    BioIntelliSense isn’t the only remote monitor on the market. Last week, the FDA cleared LifeSignals LX1550 Multiparameter
    Remote Monitoring Platform, w h i c h i s m a d e u p o f a s i n g l e - u s e w e a r a b l e b i o s e n s o r . T h e t o o l i s a b l e t o
    measure electrocardiography, heart rate, respiration rate, skin temperature, and body posture data for up to five days.
    Others in the space include Huma, which landed $130 million in Series C funding in May, TytoCare, which recently closed
    $50 million, 100plus, which is backed by $25 million in seed funding, and Biofourmis, which closed $100 million in Series C
    funding.
    Source : [online] https://www.mobihealthnews.com/news/remote-monitoring-startup-biointellisense-raises-45-
    million-series-b-funding
    Answer ALL the questions in this section.
    Question 1 (25 Marks)

    Critically analyse potential threats to the BioSticker wearable in relation to cyber-attacks and propose how BioSticker could
    be protected against such attacks.

    Question 2 (25 Marks)

    Explore and analyse various ways in which BioSticker will disrupt the healthcare market.
    Question 3 (25 Marks)

    Suppose that the healthcare records are managed using blockchain-based records management systems, examine
    practical ways in which the wearables, BioSticker and BioButton would solve record management problems for patients as
    well as that of the medical records management professionals.

    Question 4 (25 Marks)

    Suppose the same technology of wearables is conceptualised and adapted to work for a motor vehicle, a car. Taking into
    consideration how it works in human beings; analyse various ways in which a car owner would benefit from this technology.

    You might also like